Type 1 Diabetes Clinical Trial
Official title:
Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes
NCT number | NCT05233592 |
Other study ID # | IRB00305567 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 8, 2022 |
Est. completion date | April 4, 2023 |
Verified date | May 2023 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Vaccines for COVID-19 are an essential part of combating the coronavirus pandemic. Vaccines "prime" the immune system against an invader (in this case the SARS-CoV-2 virus) by causing a temporary increased immune or inflammatory response. Inflammation can temporarily increase sugar levels and/or insulin requirements among patients with diabetes. The purpose of this study is to investigate whether the "booster" COVID-19 vaccine dose causes temporarily increased sugar levels and/or insulin dose requirements among patients with Type 1 Diabetes (T1D).
Status | Completed |
Enrollment | 21 |
Est. completion date | April 4, 2023 |
Est. primary completion date | April 4, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adult (age =18yo) 2. Type 1 Diabetes 3. Is already fully vaccinated against COVID-19 (e.g. received 2 doses of Pfizer or Moderna or one dose of Johnson & Johnson) 4. Available to receive a COVID-19 booster vaccine (first or second booster dose) Exclusion Criteria: 1. Has already received a COVID-19 booster vaccine dose 2. Known physical or psychological disorder which would prohibit the patient from complying with the study procedures (e.g. allergy to adhesive, profound skin disorder, known to have severe adverse reactions previously to CGMs, poorly controlled schizophrenia, etc.) 3. Recent, acute, or chronic medical condition which may significantly affect insulin resistance or measurements of glucose (e.g. severe cirrhosis, acute infection, cancer on chemotherapy, etc.) 4. On a medication known to cause significant hyperglycemia (e.g. supraphysiologic dose of steroids) or negatively affect readings of CGM (e.g. supraphysiologic doses of acetaminophen (e.g. >4g/d)). 5. Pregnant or actively trying to get pregnant 6. Planned PET, CT, or MRI test in the next 10 days 7. Unwilling or unable to keep track of insulin usage during the study |
Country | Name | City | State |
---|---|---|---|
United States | Cardiovascular Specialists of Central Maryland | Columbia | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | DexCom, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Post-hoc ANOVA | One-way Repeated Measures ANOVA will be used to assess changes in secondary outcome variables over time. | Days 1 to 5 post-vaccine as compared to baseline | |
Other | Post-hoc t-test | Assess whether secondary variables from individual days are significantly different from baseline. | Days 1 to 5 post-vaccine as compared to baseline | |
Primary | Total Daily Insulin Resistance (TDIR) | Mean glucose multiplied by total daily insulin dose. | Day 1 post-vaccine as compared to baseline | |
Secondary | Change in TDIR | Mean glucose multiplied by total daily insulin dose. | Days 1 to 5 post-vaccine as compared to baseline | |
Secondary | Change in Time in Range | Percentage of time that the participant's blood sugar is between 70-180mg/dL. | Day 1 post-vaccine as compared to baseline | |
Secondary | Change in Daily Insulin Requirement | Total Daily insulin dose. | Day 1 post-vaccine as compared to baseline | |
Secondary | Change in Time in Hyperglycemia | Percentage of time that participants' sugar level is above 180mg/dL. | Day 1 post-vaccine as compared to baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 | |
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|